CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial

An ongoing prospective phase 2 study is evaluating the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphoma. As of February 2025, 31 patients had been enrolled, with preliminary results suggesting promising efficacy and a favorable safety profile.